Explore insightful data coverage on more than 600 facilities, with information on different manufacturing related parameters of Biopharma and CMO/CDMOs in the East Asia, in easily accessible and understandable formats.
The data is covered across several parameters to provide real-time insights into bioprocessing industry such as the locations of the biologics facilities, production capacity of Biopharma and CMOs, upstream and downstream processing capabilities, adoption of bioprocessing equipment and technologies and exclusive information on company’s future plans and investment. Some of the key companies included in this tracker are Samsung Biologics, Lonza, Beigene, Patheon, ExoCoBio, Bioworkshops and Biocina.
The tracker is underpinned by user-friendly visuals to allow users to filter through data by country, company, product type, scale of operation/phases of development, manufacturing capabilities.
It has over 600 biopharma and CMO/CDMO facilities data from East Asian countries. We ensure delivery of highly-qualified research as we tap into our database of 62000+ life science professionals curated over a decade.
The tracker provides an in-depth overview of the upcoming competition in the East Asia Bioprocessing market. Through this tracker IMAPAC aims to assist organizations to keep track of their competitors, identify any opportunities for collaboration or investments for development or manufacturing of large molecules in the East Asia region, aiding in key strategic decisions for biopharma business industry.
The data in this tracker is researched and validated using primary and secondary research. The data is collected through multiple scientific and non-scientific sources including live discussions with experts through IMAPAC’s events and research reports, survey polls, company websites, press releases, publicly available information, regulatory database and many more.
We have a database of key decision makers from the biopharma companies across the region. We host industry surveys with bioprocessing leaders of CMOs and Biopharma, and host primary interviews with Heads of Manufacturing, R&D, Process Development Heads and multiple stakeholders in the companies to gather data as well as validate that data using our primary research analysts.
Throughout the year, we keep in touch with the KOLs through telephonic Conversation, with Q&A sessions with high profile biopharma professionals, for example CSO/CTO profiles. Apart from telephonic conversations, we send a list of questions which these experts fill in detail and send back to us.
We have dedicated analysts who gather data. The data included in the tracker is validated through primary research (interviews, phone calls) with stakeholders which is then validated by IMAPAC’s research analysts to ensure the accuracy of the data.